within Pharmacolibrary.Drugs.ATC.N;

model N06AA12
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 1.4666666666666668e-05,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0094,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0053,
    Tlag           = 600,            
    Vdp             = 0.016800000000000002,
    k12             = 1.02,
    k21             = 1.02
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06AA12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Doxepin is a tricyclic antidepressant primarily used in the treatment of major depressive disorder, anxiety disorders, and insomnia. It is approved for use in several countries and is known to have antihistaminic, anticholinergic, and sedative properties. It is still in clinical use today, particularly for depression and sleep disorders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after oral administration of doxepin tablets.</p><h4>References</h4><ol><li><p>Weber, J, et al., &amp; McCormack, PL (2010). Low-dose doxepin: in the treatment of insomnia. <i>CNS drugs</i> 24(8) 713–720. DOI:<a href=&quot;https://doi.org/10.2165/11200810-000000000-00000&quot;>10.2165/11200810-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20658801/&quot;>https://pubmed.ncbi.nlm.nih.gov/20658801</a></p></li><li><p>Puzantian, T (1998). Mirtazapine, an antidepressant. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 55(1) 44–49. DOI:<a href=&quot;https://doi.org/10.1093/ajhp/55.1.44&quot;>10.1093/ajhp/55.1.44</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9437474/&quot;>https://pubmed.ncbi.nlm.nih.gov/9437474</a></p></li><li><p>Yan, JH, et al., &amp; Midha, KK (2002). Absolute bioavailability and stereoselective pharmacokinetics of doxepin. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 32(7) 615–623. DOI:<a href=&quot;https://doi.org/10.1080/00498250210131879&quot;>10.1080/00498250210131879</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12162857/&quot;>https://pubmed.ncbi.nlm.nih.gov/12162857</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06AA12;
